Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
Next >
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
November 03, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
November 01, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
October 31, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
October 26, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
October 25, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
October 23, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
DMTTF
TSX-V:DMT
Small Pharma Obtains Final Order Approving Arrangement
October 17, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
DMTTF
TSX-V:DMT
Cybin Announces Results of Annual and Special Meeting of Shareholders
October 12, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
October 06, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
October 04, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
October 03, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 27, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
September 26, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Cantor Global Healthcare Conference
September 25, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Date of Annual and Special Meeting of Shareholders
September 21, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
September 21, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
September 05, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Acquire Small Pharma Inc.
August 28, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
DMTTF
TSX-V:DMT
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
August 23, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
August 17, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
August 15, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports First Quarter Financial Results and Recent Business Highlights
August 14, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Closing of Overnight Marketed Public Offering of Units
August 04, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
August 02, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
August 01, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Overnight Marketed Public Offering of Units
July 31, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 27, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
July 26, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
July 24, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
July 20, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.